| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Virology |
| Manuscript Type |
Randomized Clinical Trial |
| Article Title |
Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Lai Wei, Fu-Sheng Wang, Ming-Xiang Zhang, Ji-Dong Jia, Alexey A Yakolev, Wen Xie, Eduard Burnevich, Jun-Qi Niu, Yong Jin Jung, Xiang-Jun Jiang, Min Xu, Xin-Yue Chen, Qing Xie, Jun Li, Jin-Lin Hou, Hong Tang, Xiao-Guang Dou, Yash Gandhi, Wen-Hua Hu, Fiona McPhee, Stephanie Noviello, Michelle Treitel, Ling Mo and Jun Deng |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Bristol-Myers Squibb |
|
|
| Corresponding Author |
Jun Deng, MD, Global Clinical Research, Bristol-Myers Squibb, 55F Wheelock Square, 1717 West Nanjing Road, Shanghai 200040, China. daniel.deng@bms.com |
| Key Words |
Asunaprevir; Daclatasvir; Direct-acting antiviral; Chronic hepatitis C; Liver disease; NS3; NS5A; Genotype 1b |
| Core Tip |
This phase 3, placebo-controlled study assessed the efficacy and safety of daclatasvir (NS5A inhibitor) plus asunaprevir (NS3/4A protease inhibitor) in treatment-naïve patients from mainland China, Russia and South Korea with hepatitis C virus (HCV) genotype 1b infection. The rate of sustained virologic response at posttreatment week 12 among patients in the immediate treatment arm was 92%, which was significantly higher than the historical comparator rate (70%). The combination was well tolerated during 24 wk of treatment. These results demonstrate that for countries such as China, where interferon-based combinations are still widely used for the treatment of HCV genotype 1b, daclatasvir/asunaprevir offers a more efficacious and tolerable alternative with a shorter treatment duration. |
| Publish Date |
2018-03-26 08:48 |
| Citation |
Wei L, Wang FS, Zhang MX, Jia JD, Yakovlev AA, Xie W, Burnevich E, Niu JQ, Jung YJ, Jiang XJ, Xu M, Chen XY, Xie Q, Li J, Hou JL, Tang H, Dou XG, Gandhi Y, Hu WH, Mcphee F, Noviello S, Treitel M, Mo L, Deng J. Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection. World J Gastroenterol 2018; 24(12): 1361-1372 |
| URL |
http://www.wjgnet.com/1007-9327/full/v24/i12/1361.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v24.i12.1361 |
